Buchumschlag

Questioning the Design of Non‐Inferiority Trials: The Strange Case for Therapeutic Drug Monitoring Absence in Phase III Trials

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Florian Lemaitre, Sébastien Lalanne, Marie‐Clémence Verdier
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Clinical Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails
von: Niels A. D. Guchelaar, et al.
Veröffentlicht: (2024)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
von: Mark J. Ratain
Veröffentlicht: (2024)

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost
von: Vaishali Sahasrabudhe, et al.
Veröffentlicht: (2025)

Bringing Trial Activities to Participants—The Trials@Home RADIAL Proof‐of‐Concept Trial Investigating Decentralization of Trials
von: Mira G.P. Zuidgeest, et al.
Veröffentlicht: (2025)

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development
von: Tanja S. Zabka, et al.
Veröffentlicht: (2025)

Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
von: Mohamed A. Kamal, et al.
Veröffentlicht: (2024)

Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
von: Yu Wu, et al.
Veröffentlicht: (2025)

Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial
von: Hung‐Kuan Yen, et al.
Veröffentlicht: (2025)

Operationalizing Decentralized Clinical Trials: Technology Insights from the Trials@Home RADIAL Proof‐of‐Concept Trial
von: Sten Hanke, et al.
Veröffentlicht: (2025)

Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs
von: Miquel Serra‐Burriel, et al.
Veröffentlicht: (2026)

Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrials.gov
von: Lars Masanneck, et al.
Veröffentlicht: (2024)

A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus
von: Gerald C. So, et al.
Veröffentlicht: (2024)

How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand‐Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic
von: Masanao Sasaki, et al.
Veröffentlicht: (2024)

Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021
von: Yoona Choi, et al.
Veröffentlicht: (2025)

Regulatory Interactions and Learnings— RADIAL the Trials@Home Proof‐of‐Concept Trial on Decentralization
von: Helga Gardarsdottir, et al.
Veröffentlicht: (2025)

Innovations and Best Practices for Therapeutic Development in Pediatric Rare Diseases: A Model‐Informed Drug Development Perspective
von: Rajesh Krishna, et al.
Veröffentlicht: (2025)

Requirements for Phase Lag in First‐In‐Human Trials in India: Proceedings of a Panel Discussion
von: Nusrat Shafiq, et al.
Veröffentlicht: (2026)

Impact of COVID‐19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective
von: Mohamed‐Eslam F. Mohamed, et al.
Veröffentlicht: (2024)

Clinical Benefit, Trials, and Regulatory Approval of Oncology Indications Under Multiple Expedited Programs for Drug Marketing in China, 2018–2024
von: Jie Zhang, et al.
Veröffentlicht: (2025)

Safety, Tolerability, and Pharmacokinetics of GMDTC for Cadmium Poisoning: A Randomized Phase 1a/1b Trial
von: Xuefeng Ren, et al.
Veröffentlicht: (2026)

Progress, Pitfalls, and Impact of AI‐Driven Clinical Trials
von: Dominika Wilczok, et al.
Veröffentlicht: (2024)

Home Is Where the Research Is: The Promise of Decentralized Clinical Trials
von: Sarah A. Holstein
Veröffentlicht: (2025)

Is a Clinical Trial With a Non‐Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK
von: Jin Dong, et al.
Veröffentlicht: (2026)

Regulatory Issues of Platform Trials: Learnings from EU‐PEARL
von: Quynh Lan Nguyen, et al.
Veröffentlicht: (2024)

Registered Clinical Trials of Ayahuasca and DMT : A Scoping Review
von: Tijana Stojanović, et al.
Veröffentlicht: (2026)

Investigational Use of Real‐World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial
von: Andrew H. Ko, et al.
Veröffentlicht: (2024)

Safety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class ClC‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
von: Titia Q. Ruijs, et al.
Veröffentlicht: (2024)

Summary Report of a Public Workshop: Case Studies of Multi‐Regional Clinical Trial Incorporating Concept of the ICH E17 Guideline
von: Nobuko Matsushima, et al.
Veröffentlicht: (2024)

CB1 Receptor Antagonist Selonabant (ANEB‐001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial
von: Andriy A. Gorbenko, et al.
Veröffentlicht: (2025)

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment
von: Sébastien Taillemite, et al.
Veröffentlicht: (2026)

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial
von: Dave Singh, et al.
Veröffentlicht: (2025)

Capturing Synergy Holistically in Psychedelic Clinical Trials: Assessing Processes in Addition to Outcomes
von: Terence H.W. Ching, et al.
Veröffentlicht: (2024)

A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization
von: Ling Xue, et al.
Veröffentlicht: (2024)

Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline
von: Akihiro Hirakawa, et al.
Veröffentlicht: (2024)

POP‐REFINE: A Comprehensive Framework for Evaluating and Optimizing Representativeness in Clinical Trials
von: Corey M. Benedum, et al.
Veröffentlicht: (2024)

Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials
von: Guotao Chu, et al.
Veröffentlicht: (2025)

A Framework for Assessing the Viability of External Control for a Single‐Arm Trial
von: Victor A. Kiri
Veröffentlicht: (2026)

Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms
von: Caroline Marra, et al.
Veröffentlicht: (2024)

From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy
von: Lisa Cuba, et al.
Veröffentlicht: (2024)

Supplementing Single‐Arm Trials with External Control Arms—Evaluation of German Real‐World Data
von: Martin Russek, et al.
Veröffentlicht: (2025)